1. Home
  2. GRML vs ATOS Comparison

GRML vs ATOS Comparison

Compare GRML & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.19

Market Cap

34.9M

Sector

N/A

ML Signal

N/A

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$2.28

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRML
ATOS
Founded
N/A
2009
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.9M
36.2M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
GRML
ATOS
Price
$0.19
$2.28
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
7.6M
133.7K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.53
52 Week High
$0.55
$7.56

Technical Indicators

Market Signals
Indicator
GRML
ATOS
Relative Strength Index (RSI) 41.63 39.28
Support Level $0.16 $0.58
Resistance Level $0.34 $2.60
Average True Range (ATR) 0.04 0.19
MACD 0.00 0.09
Stochastic Oscillator 27.86 26.83

Price Performance

Historical Comparison
GRML
ATOS

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: